Furthermore, we also confirmed that HER2+ breast cancer samples (as determined by immunohistochemistry, IHC staining) have high PRECISE RTK scores compared to other breast samples and can potentially be used as a complementary proteomics surrogate for determining HER2- status. This evidence concerns the gene ERBB2 and breast carcinoma.